Alivus Life Sciences Achieves Flawless USFDA Inspection at Dahej API Facility May 30, 2025
Alivus Life Sciences' Active Pharmaceutical Ingredient (API) facility in Dahej, Gujarat, successfully completed a United States Food and Drug Administration (USFDA) inspection with zero Form 483 observations. This outcome validates the facility's adherence to Good Manufacturing Practices (GMP) and demonstrates the company's commitment to quality and regulatory compliance. The successful inspection potentially strengthens Alivus Life Sciences' position in the global pharmaceutical market, particularly for products destined for the U.S. market, and builds confidence among regulators, partners, and customers.
Alivus Life Sciences Reports Strong Q4 Results, Recommends Dividend May 15, 2025
Alivus Life Sciences Receives USFDA EIR with VAI Status for Ankleshwar Facility Apr 04, 2025
Alivus Life Sciences to Acquire 9.21% Stake in Torrent Urja 19 for ₹156 Crore Apr 03, 2025